Marc Stapley Sells 2,000 Shares of Illumina, Inc. (NASDAQ:ILMN) Stock
Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley sold 2,000 shares of the stock in a transaction on Friday, July 14th. The shares were sold at an average price of $173.56, for a total transaction of $347,120.00. Following the transaction, the executive vice president now directly owns 39,941 shares in the company, valued at approximately $6,932,159.96. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Marc Stapley also recently made the following trade(s):
- On Monday, June 12th, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $170.85, for a total transaction of $341,700.00.
Illumina, Inc. (NASDAQ ILMN) opened at 173.66 on Wednesday. The company’s 50-day moving average is $175.82 and its 200-day moving average is $170.20. Illumina, Inc. has a 12 month low of $119.37 and a 12 month high of $189.48. The stock has a market capitalization of $25.35 billion, a PE ratio of 35.15 and a beta of 0.84.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.64. Illumina had a net margin of 30.75% and a return on equity of 21.21%. The company had revenue of $598 million for the quarter, compared to analysts’ expectations of $590.51 million. During the same period in the prior year, the business earned $0.71 EPS. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. Equities research analysts forecast that Illumina, Inc. will post $3.63 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/marc-stapley-sells-2000-shares-of-illumina-inc-nasdaqilmn-stock/1451620.html.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Jennison Associates LLC boosted its position in shares of Illumina by 69.0% in the first quarter. Jennison Associates LLC now owns 5,254,274 shares of the life sciences company’s stock valued at $896,589,000 after buying an additional 2,144,576 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Illumina by 3.0% in the first quarter. Vanguard Group Inc. now owns 9,648,842 shares of the life sciences company’s stock valued at $1,646,479,000 after buying an additional 285,379 shares during the last quarter. TIAA CREF Investment Management LLC boosted its position in shares of Illumina by 40.1% in the first quarter. TIAA CREF Investment Management LLC now owns 948,121 shares of the life sciences company’s stock valued at $161,787,000 after buying an additional 271,461 shares during the last quarter. Baird Financial Group Inc. boosted its position in shares of Illumina by 1,110.5% in the first quarter. Baird Financial Group Inc. now owns 279,120 shares of the life sciences company’s stock valued at $47,629,000 after buying an additional 256,061 shares during the last quarter. Finally, Teachers Advisors LLC boosted its position in shares of Illumina by 60.7% in the first quarter. Teachers Advisors LLC now owns 384,300 shares of the life sciences company’s stock valued at $65,577,000 after buying an additional 145,231 shares during the last quarter. Institutional investors own 93.73% of the company’s stock.
Several equities analysts recently commented on ILMN shares. Vetr lowered shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $188.84 target price on the stock. in a report on Monday, March 27th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $191.00 target price on the stock in a report on Tuesday, April 4th. Leerink Swann reaffirmed a “buy” rating on shares of Illumina in a report on Wednesday, April 5th. TheStreet raised shares of Illumina from a “c+” rating to a “b” rating in a report on Thursday, April 6th. Finally, Bank of America Corporation increased their target price on shares of Illumina from $175.00 to $195.00 and gave the company a “buy” rating in a report on Tuesday, April 11th. Four research analysts have rated the stock with a sell rating, ten have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Illumina currently has a consensus rating of “Hold” and a consensus price target of $166.54.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.